| Variable . | Summary (N = 1,483) . |
|---|---|
| Age (y) | 75 (18, 101) |
| Sex | |
| Male | 649 (43.8%) |
| Female | 834 (56.2%) |
| APOE genotype | |
| ε2/ε2 | 4 (0.3%) |
| ε2/ε3 | 212 (14.4%) |
| ε2/ε4 | 49 (3.3%) |
| ε3/ε3 | 857 (58.0%) |
| ε3/ε4 | 333 (22.5%) |
| ε4/ε4 | 22 (1.5%) |
| CLEC3B rs13963 genotype | |
| G/G | 645 (43.5%) |
| G/A | 603 (40.7%) |
| A/A | 235 (15.8%) |
| Variable . | Summary (N = 1,483) . |
|---|---|
| Age (y) | 75 (18, 101) |
| Sex | |
| Male | 649 (43.8%) |
| Female | 834 (56.2%) |
| APOE genotype | |
| ε2/ε2 | 4 (0.3%) |
| ε2/ε3 | 212 (14.4%) |
| ε2/ε4 | 49 (3.3%) |
| ε3/ε3 | 857 (58.0%) |
| ε3/ε4 | 333 (22.5%) |
| ε4/ε4 | 22 (1.5%) |
| CLEC3B rs13963 genotype | |
| G/G | 645 (43.5%) |
| G/A | 603 (40.7%) |
| A/A | 235 (15.8%) |
Notes: The sample median (minimum, maximum) is given for age. Information was unavailable regarding APOE genotype for six patients.
| Variable . | Summary (N = 1,483) . |
|---|---|
| Age (y) | 75 (18, 101) |
| Sex | |
| Male | 649 (43.8%) |
| Female | 834 (56.2%) |
| APOE genotype | |
| ε2/ε2 | 4 (0.3%) |
| ε2/ε3 | 212 (14.4%) |
| ε2/ε4 | 49 (3.3%) |
| ε3/ε3 | 857 (58.0%) |
| ε3/ε4 | 333 (22.5%) |
| ε4/ε4 | 22 (1.5%) |
| CLEC3B rs13963 genotype | |
| G/G | 645 (43.5%) |
| G/A | 603 (40.7%) |
| A/A | 235 (15.8%) |
| Variable . | Summary (N = 1,483) . |
|---|---|
| Age (y) | 75 (18, 101) |
| Sex | |
| Male | 649 (43.8%) |
| Female | 834 (56.2%) |
| APOE genotype | |
| ε2/ε2 | 4 (0.3%) |
| ε2/ε3 | 212 (14.4%) |
| ε2/ε4 | 49 (3.3%) |
| ε3/ε3 | 857 (58.0%) |
| ε3/ε4 | 333 (22.5%) |
| ε4/ε4 | 22 (1.5%) |
| CLEC3B rs13963 genotype | |
| G/G | 645 (43.5%) |
| G/A | 603 (40.7%) |
| A/A | 235 (15.8%) |
Notes: The sample median (minimum, maximum) is given for age. Information was unavailable regarding APOE genotype for six patients.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
